Pfizer: US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50-59, building on earlier recommendations for older populations. read more